Document is current
Any future updates will be listed below
-
Authors
Aarsetøy, Reidun http://orcid.org/0000-0003-3266-7419
Omland, Torbjørn
Røsjø, Helge
Strand, Heidi
Lindner, Thomas
Aarsetøy, Hildegunn
Staines, Harry
Nilsen, Dennis W. T.
-
Funding
Funding for this research was provided by:
Helse Vest (911199)
Laerdal Foundation for Acute Medicine
- License Information
-
More Information
Article History
Received: 26 May 2020
Accepted: 20 July 2020
First Online: 24 August 2020
Ethics approval and consent to participate
: Informed consent was collected retrospectively. All survivors gave written, informed consent. If the patient did not regain consciousness before death, the next-of-kin were asked for consent on the patient’s behalf. This study was approved by the Regional Board of Research Ethics and the Norwegian Health Authorities, conducted in accordance with the Helsinki Declaration of 1975, as revised in 1989.
: Not applicable.
: T.O. and H.R. are partners in a patent application filed by the University of Oslo regarding the use of secretoneurin as a biomarker in cardiovascular disease and in patients with critical illness. H. R and T.O. have financial interests in CardiNor AS, which holds the license to commercialize secretoneurin. T.O. and H.R. have also received personal payments from CardiNor AS. H. R have also received personal fees from Novartis and Thermo Fisher BRAHMS. T. O has received honoraria and research support from Roche Diagnostics via Akershus University Hospital.
